COVID-19 Medication Options Monoclonal antibodies
Monoclonal antibody treatment can be used in people 12 years of age and older who weigh at least 88 pounds (40 kg) who are at high risk for severe COVID-19, including hospitalization or death for:
● Treatment of mild to moderate symptoms of COVID-19. To be eligible, patients must:
○ Test positive for SARS-CoV-2.
○ Be within 10 days of the start of their symptoms.
○ Not be hospitalized.
● Prevention of COVID-19 in people who have had close contact or are at high risk of being in close contact with someone with COVID-19, such as people in the same institutional setting (for example, nursing homes or prisons) where COVID-19 is circulating.
To be eligible, people:
○ Must not be fully vaccinated against COVID-19 or
○ Are not expected to build up enough of an immune response to the complete COVID-19 vaccination (for example, someone with immunocompromising conditions, including someone who is taking immunosuppressive medications).
How can I get monoclonal antibody treatment?
Talk to your doctor or other health care provider about treatments that are right for you, including if you have other medical conditions that are not listed above.
The Minnesota Resource Allocation Platform (MNRAP) is an online tool that connects people and health care providers with COVID-19 medications. People, their caregivers, or their health
care providers can use MNRAP to find out which medications are available, whether they will help the person, and whether the person is able to get medication.
If someone can get a COVID-19 medication, MNRAP passes along information on their behalf to a health care facility that can give it. A final decision about whether someone can get a medication is up to the health care provider at that facility.
There are new treatments under development for COVID-19 that are administered orally (by mouth). They have not yet received emergency use authorization from the FDA. Once an authorization is issued, the U.S. government plans to begin allocating supplies to states for distribution. MDH is in the process of planning this distribution. Further details will be available once an emergency use authorization has been issued and Minnesota has received details of the allocation.
New monoclonal antibody for prevention
A new monoclonal antibody for the prevention of COVID-19 is under development that may be
used in immunocompromised patients and patients who have a medical contraindication to receiving a vaccine for COVID-19. It has not yet received emergency use authorization from the FDA. Once an authorization is issued, the U.S. government plans to begin allocating supplies to states for distribution. MDH is in the process of planning this distribution. Further details will be available once an emergency use authorization has been issued and Minnesota has received details of the allocation.
Remdesivir and convalescent plasma
These medication options are typically for people with severe COVID-19 who require hospitalization.
For more information on COVID-19 treatments and vaccines, please visit Combat COVID provided by the U.S. Department of Health and Human Services (HHS)